Cicor Technologies Ltd / CH0008702190

Ad hoc announcement pursuant to Art. 53 LR

Bronschhofen, October 15, 2025 – The Cicor Group (SIX Swiss Exchange: CICN) continued its growth path during the third quarter of 2025. Quarterly sales increased by 33% to CHF 160.1 million (YTD: CHF 440.8 million, an increase of 25.4%). The strong order intake of CHF 174.5 million corresponds to a book-to-bill rate of 1.09.

Cicor was able to further strengthen its position in the third quarter of 2025 as one of Europe’s leading development and manufacturing partners for complex electronics in its core markets of medical technology, industrial applications, as well as aerospace and defence (A&D). Organically, the Cicor Group's sales declined by 1.1% in the third quarter of 2025. This is entirely attributable to the Advanced Substrates (AS) division. It was mainly due to individual customers in the medical sector reducing their inventories and the closure of the Ulm site. The Electronic Manufacturing Services (EMS) division achieved organic growth in the third quarter. Cicor once again gained market share and was able to significantly counter the overall trend in the EMS market, which saw in Europe a 8.1% year-on-year decline in the first half of 2025.  This trend is expected to be further strengthened in the last quarter of the year by new orders that are already in the pipeline, particularly in the A&D sector. 

The Cicor Group is a globally active provider of full-cycle electronic solutions from research and development to manufacturing and supply chain management. Cicor’s approximately 4,400 employees in 13 countries are serving leaders from the medical, industrial and aerospace & defence industries. Cicor creates value to its customers through the combination of customer-specific development solutions, high-tech components, as well as electronic device manufacturing. The shares of Cicor Technologies Ltd. are traded at the SIX Swiss Exchange (CICN). For further information, please visit the website www.cicor.com.